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With  the  completion  of  the  Human  Genome  Project,  a  large  wealth  of 
knowledge was  gained  about the  basic  biology  of humans. The  understanding of 
genetics has  grown exponentially since then.  Hidden in the DNA of every person  is 
information about  potential  health  risks.  If this  information is  accurate enough,  it 
could become an  extremely valuable asset to underwriters and actuaries at life and 
health insurance companies. This  rapid  increase  in  knowledge  of genetic diseases 
has  also  lead  to fears  among some  considering buying insurance. Some  may think 
that they will be  treated unfairly by  insurers if they take a genetic test. This  paper 
investigates  how insurance  companies  can  use  genetic information and  how they 
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Mark, Aaron, CJ  and Fabi for their help this semester. The way that health and life insurance companies decide what an applicant 
should pay is called underwriting. To underwrite someone, the insurer would like to 
have as much information about the applicant as possible. Now, technology is 
rapidly advancing in nearly every area. One area in particular that may be useful for 
insurance companies is the field of genetics. In everyone's genes lies a great wealth 
of information about them. Perhaps, this information could be used to more 
accurately underwrite those seeking life or health insurance. However, the idea of 
insurance companies gaining access to our genetic information has lead to some 
controversy. Some people fear that they may be unfairly charged more or denied 
coverage. Is this the case? Are their worries legitimate? First of all, we will see need 
some information about what these genetic tests actually are. Also, there are some 
laws in place regarding this subject. Finally, we will look at insurance companies' 
current practices. 
Genetic Tests 
Genetic testing or DNA testing is a medical test that analyzes a person's 
genetic information. They can detect changes in genes, chromosomes, or proteins.. 
The results of genetic tests can be used to confirm or deny the presence of a 
suspected genetic disease, predict probability of developing a disease, and identify 
carriers of genetic disease .There are currently over 900 tests available and over 
1500 diseases can be identified through these various tests. 
Newborn screening is used just after birth to identify genetic disorders that 
can be treated early in life. Millions of babies are tested each year in the United 
States. All states currently test infants for phenylketonuria (a genetic disorder that 
1 causes mental retardation if left untreated} and congenital hypothyroidism (a 
disorder of the thyroid gland). Most states also test for other genetic disorders. 
Diagnostic testing is  used to identify or rule out a specific genetic or 
chromosomal condition. In many cases, genetic testing is used to confirm a diagnosis 
when a particular condition is suspected based on physical signs and symptoms. 
Diagnostic testing can be performed before birth or at any time during a person's 
life, but is not available for all genes or all genetic conditions. The results of a 
diagnostic test can influence a person's choices about health care and the 
management of the disorder. 
Carrier testing is used to identify people who carry one copy of a gene 
mutation that, when present in two copies, causes a genetic disorder. This type of 
testing is offered to individuals who have a family history of a genetic disorder and to 
people in certain ethnic groups with an increased risk of specific genetic conditions. 
If both parents are tested, the test can provide information about a couple's risk of 
having a child with a genetic condition. 
Prenatal testing is used to detect changes in a fetus's genes or chromosomes 
before birth. This type of testing is offered during pregnancy if there is an increased 
risk that the baby will have a genetic or chromosomal disorder. In some cases, 
prenatal testing can lessen a couple's uncertainty or help them make decisions about 
a pregnancy. It cannot identify all possible inherited disorders and birth defects, 
however. 
Preimplantation testing, also called preimplantation genetic diagnosis {PGD}, 
is a specialized technique that can reduce the risk of having a child with a particular 
genetic or chromosomal disorder. It is used to detect genetic changes in embryos 
2 that were created using assisted reproductive techniques such  as in-vitro 
fertilization. In-vitro fertilization involves removing egg cells from a woman's ovaries 
and fertilizing them with sperm cells outside the body. To perform preimplantation 
testing, a small number of cells are taken from these embryos and tested for certain 
genetic changes. Only embryos without these changes are implanted in the uterus to 
initiate a pregnancy. 
Predictive and presymptomatic types of testing are used to detect gene 
mutations associated with disorders that appear after birth, often later in life. These 
tests can be helpful to people who have a family member with a genetic disorder, 
but who have no features of the disorder themselves at the time of testing. 
Predictive testing can identify mutations that increase a person's risk of developing 
disorders with a genetic basis, such as certain types of cancer. 
Presymptomatic testing can determine whether a person will develop a 
genetic disorder, before any signs or symptoms appear. The results of predictive and 
presymptomatic testing can provide information about a person's risk of developing 
a specific disorder and help with making decisions about medical care. 
Forensic testing uses DNA sequences to identify an  individual for legal 
purposes. Unlike the tests described above, forensic testing is not used to detect 
gene mutations associated with disease. This type of testing can identify crime or 
catastrophe victims, rule out or implicate a crime suspect, or establish biological 
relationships between people (for example, paternity). 
For the purpose of insurance and underwriting, diagnostic, presymptomatic 
and predictive tests would be the most important. Now that we know about the 
3 tests themselves, let's look at the laws regarding how insurance companies can use 
the results. 
laws on genetics and insurance. 
On the federal level in the United States, a legislation known as The Genetic 
Information Nondiscrimination Act (GINA) of 2008, protects Americans from 
discrimination by health insurance companies and employers based on genetic 
information. Under this act, health insurers are prohibited from requesting or 
requiring genetic testing by the insured or their family. Also, an insurer may not 
restrict enrollment or raise premiums based on genetic tests. GINA does not apply to 
life, disability or long term care insurance. Also, GINA only applies to asymptomatic 
individuals. 
State laws about the use of genetic information for insurance purposes vary 
greatly. Most laws in place today may restrict insurers from activities like using 
genetic information to determine eligibility or set premiums, requiring genetic 
testing of applicants, or disclosing genetic information without consent. As far as 
health insurance, almost every state has some form of anti-discrimination law in 
place and if they don't, GINA acts as a "floor" or minimum level of protection. Only a 
handful of states have laws pertaining to genetic discrimination for life, disability and 
long term care insurance. The table below shows which states restrict such 
discrimination. 
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Another type of law about genetic testing that few states have adopted 
concerns the surreptitious collection of DNA or genetic information. This is the 
collection of DNA, analysis of samples or the disclosure of genetic information 
without the consent of the individual that was tested. A few states have laws in place 
that restrict surreptitious collection of DNA for health and employment related 
purposes as well as parentage proceedings. GINA again covers all states in this 
matter as well. The surreptitious collection of DNA is illegal for health insurance 
purposes. However, no states have these laws for life insurance purposes. That 
means any state In the table above with no checked boxes allows insurers to 
discriminate based on genetic information and it doesn't matter how they acquired 
it. 
So we've seen that GINA prevents any discrimination for health insurance, 
but there are hardly any laws for life insurance. Now we just need to know if life 
insurance companies actually discriminate against people based on their genetic 
tests. To understand this, we need to know a little more about the underwriting 
process. 
Underwriting process 
Many Americans have some form of life insurance through their 
employers as  a benefit. It is  usually a small amount that is enough to pay for 
funeral costs but not much more. In order to cover the costs of things like 
college tuition and mortgage payments people need to turn to privately 
7 underwritten life insurance . Everyone wanting life insurance must decide when 
to buy it and how much to buy  They also need to decide which type of 
insurance to purchase. The products range from relatively cheap term insurance 
to high cash value single premium whole life with many different types in 
between. When choosing which type to buy, people must consider their current 
income, coverage needs and if they want a cash value policy or a term policy 
and invest the difference  There are more than 1,200 insurance companies in 
the U.S.  competing to meet the specific needs of all consumers. 
The only thing common to all forms of life insurance is  the transfer of 
financial loss from the insured to the insurer in the event of a premature death. 
To  offer this, the insurance companies need to be  able to determine the risk 
associated with each applicant and invest wisely so  that they will have enough 
money to pay future claims. Different groups of people pay different prices 
depending on the life expectancy or risk of death associated with them. Life 
expectancy depends on age, gender, life style, occupation and health 
conditions. 
The  purpose of underwriting, or risk selection, is  to decide into which 
group to place an applicant. Most people with no history of disease or major 
risk factor are placed in a large group considered to have standard mortality. 
The premium assigned to a group is  determined by the expected rate of death. 
People with different diseases may be placed in the same group if they have the 
same life expectancy.  For example, someone with diabetes and a person with 
coronary artery disease have double the expected annual mortality so  they 
would both pay the same amount. 
8 The job of underwriters is to determine life expectancy based on 
medical, occupational and other factors that might affect life expectancy. It is 
important that the insurance company has knowledge of the applicant's 
situation in order to accurately evaluate the risk of mortality. With so  many 
companies competing to sell life insurance, underwriters must be accurate to 
place an attractive price on the policy. 
All insurance companies have different business models, investment 
philosophies, and target markets. Some sell mostly term insurance to younger 
crowds. Others sell mostly high cash value insurance to more affluent people. 
Some companies only want to insure those with low mortality rates while 
others aren't so  picky. This competitive market allows consumers to have many 
options when buying insurance even if they have a disease or some other risk 
factor.  Companies have medical staff and underwriting specialists that stay 
informed on the impact new medical knowledge, disease treatments and tests 
have on mortality. When an applicant has a certain known disease, it is  up to 
the medical underwriter to assess the risk and its impact on mortality. The free 
market aspect of the insurance industry ensures that all customers can get the 
best price, regardless of their medical condition. 
People in large groups will die at a predictable rate. This holds true 
whether the group is composed of healthy individuals or if everyone in the 
group has the same disease. Life insurance companies use mortality tables (also 
called life tables) for each risk category. A mortality table shows the number of 
deaths expected in each year of life for a group of people. Below is a shortened 
mortality table to serve as  an example. Almost all mortality tables will show 
9 mortality rates until the age of 100 with some going to 120.  This particular 
table shows the mortality risk for the entire United States population only until 
age 45. Other tables will be more specific in regards to gender, race, smoking 
habits and health risks. 
life table for total population: United States, 2003 
Age 
Probability of 
Number alive at 
Number dying 
Expectation of 
x 
dying between 
age x 
between ages x 
life at age x 
ages x and x+1  and x+1 
0  0.006865  100,000  687  77.5 
1  0.000465  99,313  46  77 
2  0.000331  99,267  33  76.1 
3  0.000259  99,234  26  75.1 
4  0.000198  99,208  20  74.1 
5  0.000168  99,189  17  73.1 
6  0.000151  99,172  15  72.1 
7  0.000142  99,157  14  71.1 
8  0.000139  99,143  14  70.2 
9  0.000134  99,129  13  69.2 
10  0.000165  99,116  16  68.2 
11  0.000147  99,099  15  67.2 
12  0.000176  99,085  17  66.2 
13  0.000211  99,067  21  65.2 
14  0.000257  99,047  25  64.2 
15  0.000339  99,021  34  63.2 
16  0.000534  98,988  53  62.3 
17  0.00066  98,935  65  61.3 
18  0.000863  98,869  85  60.3 
19  0.000925  98,784  91  59.4 
20  0.000956  98,693  94  58.4 
21  0.000965  98,598  95  57.5 
22  0.000987  98,503  97  56.5 
23  0.000953  98,406  94  55.6 
24  0.000955  98,312  94  54.7 
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Source: National Vital Statistics Report, Vol. 54, No. 14, April 19,2006 
An  underwriter must be  able to interpret medical advances differently 
than traditional medicine. For example, suppose a new medicine was 
introduced that treated a certain disease and claimed that among 40 year old 
patients, 99.5% survived the first year of treatment. This may seem like a large 
portion of the patients are survivors, but when the numbers are examined more 
closely, the results aren't so  great. A 99.5% survivability means that out of 1000 
patients, 5 will die within a year. From the chart above, the standard population 
would only experience 2.026 deaths per 1000 people. While a 99.5% chance of 
11 surviving some disease may sound good, the risk of death is  actually 2,5 times 
higher than a person with no disease. 
Another example of why mortality tables are so important in figuring the 
price an applicant should pay deals with tobacco use, While intuition may say 
that someone who smokes will only have an  increased risk of mortality at higher 
ages, the truth is  different. In fact, smoking and most diseases increase the 
death rate in a consistent fashion for each interval of life. The table below 
shows the expected deaths of smoking and non-smoking men. 
Number of expected deaths per 1,000 men per year for smokers and 
non-smokers 
Age  Non-Smoker  Smoker 
30  0,32  0.68 
50  1.08  2.16 
70  5,94  11.98 
Source: Medical Underwriting, Robert K.  Gleeson, MIT Press 
The table shows that for any age, a non-smoker is  half as  likely to die 
before his next birthday as  a smoker. This is counterintuitive to those who think 
a smoker's risk of mortality only increases at higher ages. Also, the very low 
mortality rates should be noted. A genetic disease that leads to only one death 
in a thousand may seem low, but to a person age  30, it would double his or her 
likelihood of death. 
Most differences in mortality for a given age, gender and smoking status 
are related to health factors. These factors could be occupational, avocational 
or habits like driving records. Insurers are interested in knowing as  much 
information about the applicant's health as  possible to insure accurate 
12 underwriting. Almost all applicants are asked questions about their current 
health, any major illnesses or surgery in the past and their family history of 
diseases. For larger amounts of insurance, saliva or blood tests may be 
implemented to test for HIV, nicotine or recreational drugs. At even higher 
amounts, blood tests may be used in order to test for disorders of lipids, 
glucose and liver or kidney functions. At still higher levels, insurers may require 
an electrocardiogram, chest radiograph or a statement from the applicant's 
physician. 
Mortality Rates and Genetic Risks 
With the completion of the Human Genome Project, a great deal has been 
learned about basic human biology. We have learned about hundred of genetic 
mutations and which diseases they may cause. Along with this knowledge came the 
fears of some who think it may be used against them. One area where people feared 
this newfound information may be used maliciously is the life insurance industry. But 
is there anything to worry about? Will more accurate genetic tests lead to higher 
insurance prices? 
Many of the concerns people have are that if they take a genetic test, they 
might pay more or be denied for life insurance. These concerns are based on a 
misunderstanding of the underwriting process. As explained earlier, underwriters 
use medical and actuarial information to determine life expectancy and an 
appropriate premium. Genetic tests give more information to the underwriter so the 
calculations can be more accurate. Currently, most genetic mutations that could 
potentially lead to diseases have little or no actuarial information attached to them. 
The probability of developing a disease is still unknown for many mutations. 
13 Life expectancy for a group of people is defined as the number of years that 
one is expected to live as determined by statistics.  A person's life expectancy is 
always changing as their age changes. As age increases so does life expectancy as 
long as there is no change in health. To determine an individual's life expectancy, an 
underwriter would examine their medical history, family history, laboratory tests, 
and lifestyle. Applicants who have an increased risk of a medical incident, such as a 
heart attack, but have not actually experienced one will have a lower life expectancy 
than someone without an increased risk. 
There are many different types of tests to help determine mortality rates. 
Very simple tests like determining obesity and high blood pressure indicate a higher 
mortality rate, and therefore a lower life expectancy. More complicated laboratory 
tests can check for hepatitis or diabetes. An individual could seem perfectly healthy 
before these diseases begin to show symptoms. Even though the person might be 
ostensibly healthy, his life expectancy would be lower than if he really was healthy. 
Genetic testing is different because it shows increased risks that may not be showing 
symptoms and may not be identified by simple medical tests or family history. 
Our knowledge of which mutations are linked to disease has increased very 
rapidly in the past few years. There are tens of thousands of known mutations. 
Clearly all cannot be listed here. To research further a database of most known 
mutations can  be looked up on websites like http://www.ncbLnlm.nih.gov/ (the 
national center for biotechnology information) and 
http://www.hgmd.cf.ac.uk/ac/index.php (the Human Gene Mutation Database at 
the Institute of Medical Genetics in Cardiff). However, there are only a few diseases 
for which we know the certainty of a disease becoming present. A few prevalent 
14 for which we know the certainty of a disease becoming present. A few prevalent 
genetic diseases have been studied for years and the probability of developing the 
disease based on the genetic mutations can  be determined. The morbidity and 
mortality rates of some of these mutations will be  discussed below. 
Breast and Ovarian Cancer 
Mutations in the BRCA1  and BRCA2 genes are known to cause an  increase in 
the risk of developing breast and ovarian cancer. Together these mutations cause 
10% of all breast cancer. The following chart shows the risk of developing breast 
cancer after a genetic test is positive for a BRCA mutation. 
BReA Mutation Increases the Risk of Cancer 
560/0-8]0/0 
"  . 
27%-440/0 
Many women might think that a positive result is  a bad thing. Relative to a 
negative test, it is not a good thing, but with an early enough detection of the 
mutation, preventative measures could lower the risks of developing cancer. A 
woman seeking life insurance with a family history of breast cancer may fear that if 
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Source: www.brconow.com she takes a BRCA test and it is positive she will have to pay a higher premium. This is 
not the case,  however. By showing that she is working with her physician to make a 
management plan, she can  lower her risks down to the same level as  the general 
population. The next table shows the survivability depending on which stage of 
breast cancer a woman has. The  numbers come from the National Cancer Data Base, 
and are based on women who were diagnosed with breast cancer in 2001 and 2002 
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Women who know they carry a BRCA mutation can be  alert and take 
preventative measures. Those who do not take the genetic test may be in stage II  or 
III  before they are diagnosed. Any woman with a family history of breast cancer 
should be encouraged to take the genetic test. If it is  negative, their insurance rates 
may be lower than if they chose not to. 
Huntington Disease 
Huntington disease is a neurodegenerative genetic disorder that affects 
cognitive ability and leads to dementia. It is  incurable and usually becomes 
symptomatic around the age of 30. The life expectancy of an individual with 
16 Huntington disease is about 20 years after the symptoms are present. It is an 
autosomal dominant disorder with 100% penetrance. An affected parent has a 50% 
chance of passing on HD to his or her child. 
Consider a 25 year old man whose father died of HD at age 50. He doesn't 
want to get a genetic test but does want life insurance. He has a 50% chance that he 
will not live to be  50 years old. In this case insurers would add a small, flat, extra 
amount to the premium for at least the first 15 years of coverage. This would cover 
the increased risk. If the symptoms of HD never showed up, the extra amount could 
be dropped. In both the case of breast cancer and Huntington disease, underwriters 
are able to place the applicant into the correct group and give them a fair price. We 
have seen in theory that underwriters could use genetic tests, but do they? 
How are genetics currently used in the insurance industry? 
While, like it has been said before, genetic testing has been advancing 
rapidly, there are still very few insurance companies utilizing them. In fact, no 
companies require them for health or life insurance. Some argue that our 
understanding of genetics is moving and changing too rapidly for statistical support 
to be established. Another reason that genetic tests are rarely used is the cost. The 
average total cost for general laboratory testing, including collection, is around $100. 
Genetic tests are much more depending on the type. The chart below shows the 
prices of several different tests available. 
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Increasing the cost of testing the applicant by even $100 more would result in 
raised premiums. So  unless the applicant is seeking a very large policy, there is 
currently no justifiable reason to order such expensive tests. In the future, however, 
it is  likely that the accuracy of the tests will improve, the costs will decrease and 
statistical information will exist on the subject. Until then, the tests will rarely be 
used by insurance companies. 
Underwriting works most efficiently when the applicant and insurer have 
the same knowledge about the applicant's medical situation. An applicant 
should not withhold information in order to pay less for insurance. Nor should 
someone forgo a genetic test out of fear that the insurance company will 
discriminate against them. If an  underwriter overcharges, the company will lose 
business to competitors. With so  much competition among companies, an 
applicant cannot be unfairly charged no matter what their condition. With 
18 genetic tests advancing in their accuracy, they will be implemented more in the 
insurance industry and lead toward better underwriting. 
The field of genetics is rapidly growing and changing every day. Many people 
are not able to stay informed on all the new advancements. They are unsure of the 
proper course of action when it comes to getting a genetic test for insurance 
purposes. They may be afraid they will face negative consequences if they take the 
test. This should not be the case, however. If someone considers genetic testing for 
any reason they should not reconsider because they think their insurance will cost 
more. Having this information can help prevent an individual from becoming ill or 
even save their life. 
19 
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